Ocugen, Inc. (NASDAQ:OCGN) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 5, 2026, Ocugen, Inc.

Ocugen (OCGN) has drawn fresh investor attention after releasing full Phase 2 ArMaDa data for OCU410, showing a 46% reduction in macular lesion growth at 12 months and no therapy related serious ...

In early May 2026, Ocugen reported Q1 2026 results showing revenue of US$1.53 million with a larger quarterly net loss of US$19.18 million, and completed a US$115 million private offering of 6.75% ...

View Ocugen Inc OCGN stock quote prices, financial information, real-time forecasts, and company news from CNN.

Ocugen OCGN is pushing three retinal gene therapy programs toward late-stage milestones, with multiple data readouts and regulatory steps clustered into 2026 and early 2027. The s ...

Ocugen (OCGN) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Ocugen (OCGN) one of those stocks right now? A quick glance ...

(“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced its intention to offer, subject to market conditions and other ...

Ocugen Inc (NASDAQ:OCGN) shares are trading higher by 25.6% to $2.06 during Monday’s session. The stock is trading higher, potentially on upward momentum, after the Third Circuit Court of Appeals last ...

Investors in Ocugen Inc (Symbol: OCGN) saw new options begin trading today, for the December 3rd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the OCGN options ...